1. Executive Summary & Investment Thesis

Altimmune, Inc. (NASDAQ: ALT; CIK: 0001326190), founded in 2002 and headquartered in Gaithersburg, Maryland, is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), obesity, and serious liver diseases. The company’s corporate identity, enterprise valuation, and future operational cash flows rest almost entirely upon a single investigational drug candidate: pemvidutide (formerly ALT-801).

Pemvidutide is an investigational peptide-based GLP-1 (glucagon-like peptide-1) and glucagon dual receptor agonist engineered in an equimolar 1:1 ratio. The molecule incorporates a proprietary synthetic peptide backbone conjugated with a 16-carbon fatty diacid moiety via a hydrophilic linker, granting an extended terminal elimination half-life of approximately 45 hours that enables convenient once-weekly subcutaneous self-administration.

In clinical evaluation, the simultaneous activation of glucagon and GLP-1 receptors is designed to produce complementary metabolic actions:

1. GLP-1 Receptor Activation: Suppresses central appetite signaling, slows gastric emptying, stimulates glucose-dependent insulin secretion, and drives robust systemic body weight loss.
2. Glucagon Receptor Activation: Accelerates hepatic lipid oxidation, increases resting energy expenditure, stimulates lipolysis, and rapidly clears liver fat deposits while mitigating peripheral muscle catabolism.

In August 2026, Altimmune officially initiated patient enrollment in its registrational Phase 3 PERFORMA clinical trial, evaluating pemvidutide in patients with biopsy-confirmed non-cirrhotic MASH and moderate-to-advanced hepatic fibrosis (stages F2 and F3). The Phase 3 program follows end-of-Phase 2 alignment with the U.S. Food and Drug Administration (FDA), which previously granted pemvidutide both Breakthrough Therapy Designation and Fast Track Designation in MASH.

flowchart TD
    subgraph EnterpriseArchitecture["Altimmune, Inc. (NASDAQ: ALT | CIK: 0001326190)"]
        direction TB
        PEM["<b>Lead Asset: Pemvidutide (ALT-801)</b><br/>Equimolar (1:1) GLP-1 / Glucagon Dual Agonist<br/>45-Hour Half-Life | Once-Weekly Subcutaneous Injection"]
        P3["<b>Phase 3 PERFORMA Trial (Initiated Aug 2026)</b><br/>Biopsy-Confirmed F2/F3 MASH | 52-Week Histologic Readout (~2029)<br/>FDA Breakthrough & Fast Track Designation"]
        P2A["<b>Phase 2 MOMENTUM (Completed)</b><br/>Obesity: 15.6% Weight Loss at 48 Weeks<br/>Lean Mass Preservation vs GI Discontinuation"]
        P2B["<b>Phase 2 ALD (Ongoing)</b><br/>Alcohol-Associated Liver Disease<br/>Hepatic Fat & Inflammation Reduction"]
        PEM --> P3 & P2A & P2B
    end

    subgraph BalanceSheetEngine["Capital Structure & Cash Burn Dynamics"]
        CASH["<b>Liquid Reserves: $518.6M</b><br/>$63.0M Cash + $263.3M ST + $192.2M LT Investments<br/>Bolstered by $281.4M Net Offering in April 2026"]
        DEBT["<b>Hercules Capital Loan: $44.7M</b><br/>$34.7M Book Value + $10M Tranche Drawn Oct 2026<br/><b>Net Cash: $473.9M ($2.44 / Share)</b>"]
        BURN["<b>Trailing Operating Cash Burn: -$76.5M TTM</b><br/>Phase 3 PERFORMA Burn Expected to Scale to $90M-$110M/Yr<br/>4-5 Year Runway to 2029 Trial Endpoint"]
        CASH --> DEBT --> BURN
    end

    subgraph ValueMarkAudit["ValueMark 100-Point Quality Gate & Valuation Determination"]
        K1["<b>Gate K1: Circle of Competence (FAIL)</b><br/>Pre-Commercial Binary Biotech | 10-Yr Cash Flows Unpredictable"]
        K2["<b>Gate K2: Sector & Fragility Screen (FAIL)</b><br/>Single-Asset Dependency vs Mega-Cap Incretin Duopoly"]
        K3["<b>Gate K3: Balance Sheet Distress (PASS)</b><br/>$473.9M Net Cash | No Immediate Maturity Wall"]
        K4["<b>Gate K4: Earnings Integrity & Dilution (FAIL)</b><br/>Chronic Dilution: Share Count +374% Over 5 Years (41M -> 194.5M)"]
        SCORE["<b>Master Value Score: 30 / 100</b><br/>Conviction Tier: Failing Quality Gate / Disqualified<br/>Peter Lynch Archetype: <i>Asset Play / Speculative Biotech</i>"]
        VAL["<b>Triangulated Fair Value: $2.84</b><br/>Klarman Bear Floor: $0.95 | Base: $2.60 | Bull: $5.20<br/>Current Price: $2.04 | Headline MOS: <b>+28.2%</b>"]
        VERD["<b>Dynamic Action Verdict: AVOID</b><br/>Rule 07 Invariant: Failed Knockout Gates Demands Strict Avoid<br/>Price Trades 115% Above Klarman Bear Liquidation Floor ($0.95)"]
        K1 & K2 & K3 & K4 --> SCORE --> VAL --> VERD
    end

    EnterpriseArchitecture ==> BalanceSheetEngine
    BalanceSheetEngine ==> ValueMarkAudit

A. Core Thesis Pillars & Two-Minute Monologue (Peter Lynch)

• Stock Archetype: Peter Lynch Asset Play transitioning to Speculative Binary Biotech. On paper, Altimmune exhibits classic Walter Schloss / Benjamin Graham statistical “net-net” attributes: with $518.6 Million in liquid cash and marketable securities against$44.7 Million in term debt, net cash stands at $473.9 Million ($2.44 per share). At the current market quotation of $2.04 per share ($396.7 Million market capitalization), the entire company trades at a negative Enterprise Value (-$77.2 Million). Mr. Market is effectively pricing the underlying operating business and its proprietary dual-agonist pipeline at less than zero.
• The Two-Minute Drill: “Altimmune is developing pemvidutide, a dual GLP-1/glucagon agonist that addresses two massive global epidemics: metabolic dysfunction-associated steatohepatitis (MASH) and obesity. In Phase 2 trials, pemvidutide demonstrated distinct metabolic differentiation: driving dramatic hepatic fat reductions (>70%), normalizing elevated liver enzymes, significantly lowering triglycerides and LDL cholesterol, and preserving precious lean muscle mass (accounting for only ~21.9% of total weight lost, compared to 30% to 40% typically seen with pure GLP-1 monotherapies like semaglutide). In April 2026, management capitalized on clinical momentum to execute an upsized public offering, raising $281.4 Million net and amassing a formidable cash cushion of$518.6 Million. However, an authentic value investor must look beyond the static balance sheet snapshot to examine the thermodynamic cash burn trajectory. Altimmune generates exactly zero commercial product revenue. Over the trailing twelve months, it burned -$76.5 Million in operational cash flow and incurred a -$91.8 Million GAAP net loss. With the Phase 3 PERFORMA trial initiated in August 2026, clinical R&D expenditures will escalate significantly. Crucially, the primary 52-week histologic biopsy endpoint will not deliver data until approximately 2029—meaning that Altimmune will burn between $300 Million and$400 Million of its cash reserves before ever submitting a New Drug Application (NDA). Furthermore, management has proven to be an aggressive share-printing engine: common shares outstanding skyrocketed from 41.0 Million in 2021 to 194.5 Million in mid-2026—a catastrophic +374% dilution in under five years. In the brutal arena of metabolic disease, Altimmune is attempting to cross the desert alone, without a Big Pharma partner, directly into the crosshairs of Eli Lilly, Novo Nordisk, Madrigal, Boehringer Ingelheim, and Viking Therapeutics. While our probability-weighted DCF model establishes an intrinsic fair value of $2.84 per share, Altimmune decisively fails three of our four mandatory Knockout Quality Gates. Trading 115$0.95 liquidation value) and scoring an anemic 30/100 on our Master Value Scorecard, ALT is uninvestable for disciplined fundamental capital and commands an unequivocal Avoid verdict.”
• Runway & Long-Term Destination: If pemvidutide reaches the commercial market by 2030, the global addressable market for MASH is projected to exceed $20 Billion. Even capturing a niche 3$600 Million to $1.0 Billion in peak annual net sales. However, the multi-year regulatory and clinical gap between late 2026 and 2029 represents a high-risk dilution tunnel.

B. The Klarman Test: Why Is It Cheap? (Source of Mispricing)

Under Seth Klarman’s framework in Margin of Safety, deep value investors must never buy an asset simply because it trades below net cash without forensic dissection of the structural market forces driving that discount:

1. The Phase 3 Timeline Void & Capital Depletion Reality: Algorithmic screeners flag ALT as a “net cash bargain” ($2.44 net cash vs$2.04 stock price). Institutional biopharma specialists, however, calculate the net present value of cash at the time of the Phase 3 readout. With the PERFORMA trial enrolling across hundreds of global sites and requiring paired liver biopsies at baseline and Week 52, annual cash burn is poised to expand from ~$76M toward$95M-$110M. By the time top-line data arrives in 2029, the current$518.6M cash hoard will be depleted to under $150M-$200M. The market is not mispricing a static pile of cash; it is pricing the rapid liquidation of that cash in high-cost clinical trials.
2. The Partnerless Vacuum: For more than two years, Altimmune management has publicly messaged its intention to secure a major global pharmaceutical partner to co-fund Phase 3 trials and spearhead worldwide commercialization. In 2026, management was forced to initiate the Phase 3 trial independently and execute a heavily dilutive equity offering. The absence of a validating Big Pharma partner signals to institutional capital that prospective acquirers inspected the Phase 2 MOMENTUM and IMPACT datasets and passed on licensing the molecule at management’s asking terms.
3. The Gastrointestinal Tolerability & Discontinuation Wall: In the Phase 2 MOMENTUM obesity trial, pemvidutide demonstrated 15.6% mean weight loss, but this was accompanied by severe gastrointestinal adverse events: nausea occurred in over 50% of patients and vomiting in over 25%. More critically, treatment discontinuation rates reached 24.1% to 26.8% in the mid-to-high dose cohorts. In a chronic, outpatient lifestyle market where Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide) have established benchmark tolerability profiles, high discontinuation rates pose a lethal commercial hurdle.
4. Structural Chronic Share Dilution: Over the trailing five-year period, Altimmune has funded its operational survival almost exclusively through relentless equity dilution. Long-term shareholders have experienced 79% purchasing power destruction as share count expanded from 41M to 194.5M. The market anticipates that any future stock price strength will be immediately met with aggressive At-The-Market (ATM) stock sales.

C. Catalysts & Value-Realization Path

• Execution of a Strategic Regional or Global Partnership: Announcing an out-licensing transaction with a major biopharmaceutical company (e.g., granting ex-U.S. rights in exchange for $150M+ upfront and substantial Phase 3 cost sharing) would instantly remove balance sheet anxiety and validate pemvidutide’s commercial potential.
• Phase 2 ALD Clinical Trial Readout: Top-line data from the ongoing Phase 2 trial in alcohol-associated liver disease demonstrating significant reductions in hepatic fat, liver stiffness, and inflammatory biomarkers would establish proof-of-concept in a second high-unmet-need indication with zero approved therapies.
• Interim Phase 3 PERFORMA Biomarker Readout: Early non-invasive biomarker data (MRI-PDFF liver fat reduction, ALT/AST normalization, and FIB-4 / ELF fibrosis score improvements) from the initial cohorts of the PERFORMA trial could re-ignite acquisition interest.
• Big Pharma M&A Speculation: Large pharmaceutical enterprises lacking proprietary incretin assets or seeking next-generation glucagon dual agonists to pair with proprietary portfolios could pursue an opportunistic takeout below historical transaction multiples.

---

2. Economic Moat, Pipeline Differentiation & Competitive Durability

• Moat Rating: None | Moat Trend: Stable / Unproven
• Moat Sources: Intellectual Property Patents (Molecule Composition of Matter to late 2030s/early 2040s), but currently zero commercial pricing power, zero customer switching costs, and zero network effects.

flowchart LR
    subgraph CompetitiveArena["Global Incretin & MASH Landscape"]
        direction TB
        LILLY["<b>Eli Lilly & Co.</b><br/>Tirzepatide (GLP-1/GIP) | 74% MASH Resolution<br/>Multi-Billion Commercial Scale"]
        NOVO["<b>Novo Nordisk A/S</b><br/>Semaglutide & CagriSema | ESSENCE Phase 3<br/>Global Manufacturing Dominance"]
        MADR["<b>Madrigal Pharmaceuticals</b><br/>Rezdiffra (Resmetirom) | FDA Approved Mar 2024<br/>First-Line Oral THR-Beta Agonist"]
        BI["<b>Boehringer Ingelheim / Zealand</b><br/>Survodutide (GLP-1/Glucagon)<br/>Direct Phase 3 Competitor in MASH"]
    end

    subgraph AltimmunePosition["Altimmune: Pemvidutide Profile"]
        PEM["<b>Pemvidutide (1:1 GLP-1/Glucagon)</b><br/>Rapid Liver Fat Clearance (>70%)<br/>Lean Mass Preservation (78% Fat Loss)<br/>LDL-C & Triglyceride Reductions"]
        HURDLES["<b>Commercial & Moat Vulnerabilities</b><br/>Zero Commercial Sales Force | Zero Revenue<br/>GI Discontinuation (24%-26%)<br/>No Big Pharma Partner | Trial Readout 2029"]
        PEM --> HURDLES
    end

    CompetitiveArena -.->|Massive Scale Advantage| AltimmunePosition

A. The Scientific Mechanism of Pemvidutide: 1:1 Incretin Balance

The core differentiating hypothesis of pemvidutide is its balanced 1:1 dual agonism of the glucagon and GLP-1 receptors. Unlike selective GLP-1 mono-agonists (such as semaglutide) which primarily reduce liver fat secondary to caloric restriction and systemic weight loss, glucagon receptor activation exerts direct, potent metabolic effects on hepatocytes:

1. Direct Hepatic Lipolysis & Beta-Oxidation: Glucagon stimulates the breakdown of intrahepatic triglycerides into free fatty acids and accelerates mitochondrial beta-oxidation, driving rapid and profound reductions in liver fat content within weeks of initiation.
2. Lean Mass Sparing Action: In the Phase 2 MOMENTUM obesity trial, body composition analysis via DXA scans revealed that 78.1% of weight lost by pemvidutide-treated patients was fat mass, with only 21.9% attributable to lean muscle mass. In contrast, standard GLP-1 therapies frequently induce up to 35% to 40% lean tissue loss. Preserving muscle mass is crucial for maintaining resting metabolic rate and preventing weight regain upon treatment cessation.
3. Cardiovascular & Lipid Improvements: Glucagon stimulates hepatic LDL receptor expression, resulting in statistically significant reductions in total cholesterol, LDL-C, and serum triglycerides—an effect that contrasts sharply with certain thyroid hormone receptor agonists or pure GLP-1 agents.

B. Competitive Threats & The Incretin Arms Race

Despite these pharmacological attributes, Altimmune possesses no economic moat:

• Commercial Pre-Emption by Madrigal’s Rezdiffra: In March 2024, the FDA granted accelerated approval to Madrigal Pharmaceuticals’ Rezdiffra (resmetirom), an oral once-daily thyroid hormone receptor-beta (THR-beta) agonist, making it the first approved medicine for non-cirrhotic MASH with moderate-to-advanced fibrosis. Rezdiffra is an oral tablet with favorable gastrointestinal tolerability that requires no subcutaneous injection. Entrenched hepatologists and gastroenterologists are rapidly establishing clinical treatment pathways around Rezdiffra.
• The Mega-Cap Biopharma Juggernauts:
  • Eli Lilly (tirzepatide) reported landmark Phase 2 SYNERGY-NASH results demonstrating that up to 74% of patients achieved MASH resolution without worsening of fibrosis, alongside up to 22.5% body weight reduction.
  • Novo Nordisk (semaglutide) is advancing its pivotal Phase 3 ESSENCE trial in MASH, with initial interim histology readouts directly setting the competitive bar.
  • Boehringer Ingelheim and Zealand Pharma (survodutide) are developing a direct rival glucagon/GLP-1 dual receptor agonist that achieved up to 83% MASH improvement in Phase 2 and is backed by Boehringer’s immense multi-billion-dollar global clinical development engine.
• The Switching Cost Void: Because pemvidutide is an unapproved investigational molecule, switching costs are non-existent. Should pemvidutide gain approval in 2030, Altimmune will face a mature market where competing commercial sales forces have locked up payer formularies, pharmacy benefit manager (PBM) preferred placement, and specialty physician prescribing habits.

C. Terry Smith Gross Margin Shield & Nick Sleep SES Flywheel

• Gross Margin Shield: Altimmune generates zero commercial revenue. Its gross profit margin is undefined (0.0%), failing Terry Smith’s foundational test for pricing power and gross margin inflation insulation.
• Scale Economics Shared (SES): The biopharmaceutical business model does not operate an SES flywheel. Commercial drug pricing in metabolic disease is negotiated through steep PBM rebate concessions. Without proprietary manufacturing facilities (Altimmune relies entirely on third-party contract manufacturers), the company enjoys no structural cost advantages over its global peers.

---

3. Financial Quality & Balance Sheet Fortress

• Financial Health Rating: Moderate (Superficially strong liquidity offset by severe ongoing cash burn and negative cash conversion)
• Liquid Cash & Marketable Securities: **$518.57 Million** ($63.01M cash + $263.27M ST investments +$192.25M LT investments)
• Total Debt Outstanding: **~$44.74 Million** ($34.74M book value as of Q2 2026 + $10.0M Tranche 3 drawn Oct 27, 2026)
• Net Cash Position: **$473.83 Million** ($2.44 per share)
• Trailing 12-Month Operating Cash Burn: -$76.51 Million
• Terry Smith 5-Year Cash Conversion: Failing / Negative

A. The 4 Knockout Quality Gates Audit (Rule 07, Section 2)

+==================================================================================================+
|                        THE 4 KNOCKOUT DISQUALIFICATION GATES: AUDIT RESULT                       |
+==================================================================================================+

[FAIL] GATE K1: THE CIRCLE OF COMPETENCE & SIMPLICITY GATE (Buffett, Munger, Pabrai, Li Lu)
       - Altimmune is a pre-commercial, clinical-stage biotechnology enterprise with zero product
         revenue. Its intrinsic valuation is 100% dependent on binary histologic biopsy outcomes
         in Phase 3 MASH trials (PERFORMA 52-week readout ~2029) and future FDA regulatory review.
       - Unit economics cannot be explained in 2 minutes with >=90% intellectual certainty.
       - 10-year cash flow forecasting is fundamentally speculative. -> FAIL (DISQUALIFIED).

[FAIL] GATE K2: THE SECTOR & FRAGILITY EXCLUSION SCREEN (Terry Smith)
       - While biotechnology is not explicitly banned like commercial banking or airlines, Rule 07
         strictly excludes single-asset biopharma enterprises characterized by binary operational
         fragility and lack of commercial customer diversification (see Rule 07 & ABVX precedent).
       - Altimmune operates in an intensely crowded incretin class dominated by mega-cap pharma
         (Eli Lilly, Novo Nordisk, Boehringer Ingelheim). -> FAIL (DISQUALIFIED).

[PASS] GATE K3: THE FINANCIAL DISTRESS & REFINANCING WALL (Graham, Marks, Ackman)
       - Total liquid cash and investments ($518.6M) dwarfs total term debt ($44.7M).
       - Net Cash stands at $473.9M ($2.44/share). Current ratio is 26.8x ($334.8M CA vs $12.5M CL).
       - Cash reserves fund current burn rate (-$76.5M/yr) for approximately 4-5 years, providing
         adequate liquidity to fund the initial phase of the PERFORMA trial. -> PASS.

[FAIL] GATE K4: FORENSIC ACCOUNTING & EARNINGS INTEGRITY GATE (Terry Smith, Graham, Munger)
       - Rule 07 Section 2 Benchmark: "Does annual Stock-Based Compensation or equity dilution dilute
         shareholders by > 3.0% per annum? Is GAAP Net Income persistently higher than OCF?"
       - Dilution Audit: Common shares outstanding expanded from 40.99M in 2021 to 194.47M as of
         June 30, 2026—an astounding +374% dilution (+36.5% annualized dilution rate).
       - In the first 6 months of 2026 alone, common shares jumped from 110.88M to 194.47M (+75.4%)
         due to the April public offering of common stock and pre-funded warrants ($281.4M net).
       - Trailing cash conversion fails (negative OCF, zero operating profits). -> FAIL (DISQUALIFIED).
+==================================================================================================+
OVERALL GATE AUDIT RESULT: THREE KNOCKOUT GATES FAILED (K1, K2, K4) -> AUTOMATIC DISQUALIFICATION

Historical SEC XBRL Financial Statements & Metrics Matrix:

The following table presents Altimmune’s audited financial results extracted directly from SEC Form 10-K and Form 10-Q filings from FY2021 through the trailing twelve months ended June 30, 2026:

Metric (USD Thousands, except per share)	FY2021	FY2022	FY2023	FY2024	FY2025	6M 2026	TTM (Q2 26)
Commercial Product Revenues	$0	$0	$0	$0	$0	$0	$0
Collaboration & Grant Revenues	$4,411	$3,747	$440	$20	$41	$0	$31
Total Revenues	$4,411	$3,747	$440	$20	$41	$0	$31
Research & Development (R&D)	$69,458	$71,833	$69,466	$68,349	$71,842	$34,847	$73,626
General & Administrative (G&A)	$16,778	$17,441	$17,678	$22,467	$22,688	$15,626	$26,630
Operating Loss (EBIT)	$(97,125)	$(86,114)	$(87,204)	$(90,796)	$(94,489)	$(50,473)	$(100,225)
Interest Expense	$(295)	$(295)	$(111)	$(25)	$(1,164)	$(2,165)	$(3,064)
Interest & Investment Income	$768	$2,423	$4,583	$3,833	$7,728	$7,427	$12,478
GAAP Net Loss	$(96,966)	$(84,773)	$(82,858)	$(87,143)	$(88,093)	$(45,388)	$(91,760)
Diluted Common Shares (Period-End, M)	40.99	49.20	70.68	72.35	110.88	194.47	194.47
Weighted Avg Diluted Shares (M)	40.89	46.12	52.88	71.05	88.10	155.12	185.44
GAAP Net Loss Per Share ($)	$(2.37)	$(1.84)	$(1.57)	$(1.23)	$(1.00)	$(0.29)	$(0.47)
Operating Cash Flow (OCF)	$(82,900)	$(73,200)	$(67,100)	$(79,848)	$(67,535)	$(45,163)	$(76,508)
Capital Expenditures (CapEx)	$(315)	$(185)	$(47)	$(0)	$(11)	$(53)	$(54)
Stock-Based Compensation (SBC)	$9,650	$10,820	$12,400	$14,393	$16,076	$6,166	$14,661
Owner Free Cash Flow (OCF-CapEx-SBC)	$(92,865)	$(84,205)	$(79,547)	$(94,241)	$(83,622)	$(51,382)	$(91,223)
Cash & Cash Equivalents	$37,143	$40,994	$49,104	$36,926	$43,760	$63,008	$63,008
Short-Term Marketable Investments	$153,000	$143,000	$108,000	$102,000	$229,696	$263,273	$263,273
Long-Term Marketable Investments	$0	$0	$0	$0	$0	$192,247	$192,247
Total Liquid Reserves	$190,143	$183,994	$157,104	$138,926	$273,456	$518,528	$518,528
Total Debt (Term Loan)	$4,400	$4,165	$4,305	$0	$34,287	$34,742	$44,742*
Net Cash (Liquid Reserves - Debt)	$185,743	$179,829	$152,799	$138,926	$239,169	$483,786	$473,786*
Total Stockholders’ Equity	$183,500	$178,200	$151,800	$123,508	$224,892	$474,208	$474,208
Return on Invested Capital (ROIC %)	-52.9%	-48.3%	-57.4%	-73.5%	-42.0%	-21.3% (Ann)	-21.1%

*Reflects carrying debt as of June 30, 2026 plus $10.0M Tranche 3 term loan drawn under Hercules facility on October 27, 2026.

B. The Hercules Capital Loan Agreement & Refinancing Terms

On May 13, 2025, Altimmune entered into a $125.0 Million Loan and Security Agreement with Hercules Capital, Inc.:

• Initial Tranche A: Drawn $15.0 Million at closing ($14.6M net).
• Tranche B: Drawn $20.0 Million in late 2025 following Phase 2 trial achievements.
• Tranche 3: On October 27, 2026, Altimmune filed Form 8-K reporting the draw of an additional $10.0 Million principal**, bringing total funded term loan debt to **$45.0 Million ($44.74M estimated carrying value net of unamortized discount).
• Interest Rate & Maturity: Variable rate tied to prime (prime + 2.75% with a minimum floor of 10.75%), resulting in an effective interest cost exceeding 11.5% and annual cash interest expense of ~$5.2 Million.
• Covenants: Requires maintaining a minimum liquidity buffer of $30.0 Million, which Altimmune currently satisfies with ease.

---

4. Capital Allocation & Management Track Record

• Return on Invested Capital (ROIC): -21.1% (EBITDA / Equity)
• **Buffett $1 Retained Earnings Test**: **Severely Failing** (Cumulative net losses exceed$694.9 Million since inception)
• Share Dilution Track Record (2021 to Mid-2026): +374.2% (40.99M to 194.47M shares)
• Capital Allocation Discipline: Failing / Value Destructive

flowchart TD
    subgraph DilutionTreadmill["Altimmune Capital Allocation Flywheel"]
        ATM["<b>Equity Dilution Machinery</b><br/>ATM Offerings & Public Underwritings<br/>Raised >$500M in Net Equity Since 2021<br/>Shares Exploded from 41.0M to 194.5M (+374%)"]
        BURN["<b>Pre-Commercial R&D Spend</b><br/>Phase 2 MOMENTUM & IMPACT ($70M/yr)<br/>Phase 3 PERFORMA R&D Ramp ($90M-$110M/yr)"]
        ACCUM["<b>Accumulated Balance Sheet Deficit</b><br/>Lifetime Net Losses: <b>-$694.9 Million</b><br/>Zero Product Revenues Realized"]
        MKT["<b>Enterprise Value Compression</b><br/>Market Cap: $396.7M | Net Cash: $473.9M<br/>Enterprise Value: <b>-$77.2M (Negative)</b>"]
        
        ATM --> BURN --> ACCUM --> MKT --> ATM
    end

A. The Buffett $1 Retained Earnings Test

Under Warren Buffett’s fundamental investment standard, management must demonstrate that every dollar retained inside the enterprise produces at least one dollar of incremental market value over time:

• Altimmune has never generated positive retained earnings. Its balance sheet carries an accumulated deficit of $(694.9) Million as of June 30, 2026.
• To fund this operational deficit, management has repeatedly tapped the capital markets, accumulating $1.175 Billion in Additional Paid-In Capital (APIC) from equity investors.
• Today, the entire enterprise commands a market capitalization of just $396.7 Million.
• Over $778 Million of contributed shareholder equity has been permanently incinerated**, meaning Altimmune has destroyed approximately **$0.66 of capital for every single dollar raised. This constitutes an absolute failure of the Buffett Test.

B. Chronic Share Dilution Surveillance

Terry Smith, Mohnish Pabrai, and Charlie Munger emphasize that long-term investment compounding is fundamentally a per-share phenomenon:

• At year-end 2021, Altimmune had 40,993,768 common shares outstanding.
• At year-end 2023, share count expanded to 70,677,400.
• At year-end 2025, share count reached 110,882,735.
• Following the April 2026 public offering of 57.5M common shares and pre-funded warrants at $4.00 per share, share count jumped to 194,474,154 shares by June 30, 2026.
• In under five years, Altimmune expanded its share base by +374.2%. An investor who bought 1.0% of Altimmune in 2021 owns just 0.21% of the company today without having sold a single share. This massive supply of stock creates persistent technical and structural resistance over common equity.

C. Executive Leadership & Governance

Altimmune is led by President and Chief Executive Officer Dr. Vipin K. Garg, who has served as CEO since November 2018. Chief Financial Officer Greg Weaver brings seasoned life science financial experience. In late October 2026 (Form 8-K filed October 27, 2026), Altimmune announced the appointment of two seasoned biopharmaceutical veterans to its Board of Directors effective November 2, 2026: Peter Greenleaf (CEO of Aurinia Pharmaceuticals) and Alex Howarth (former COO of Gossamer Bio). While governance additions bring late-stage commercial acumen, insider equity ownership remains low (<3% of outstanding shares), meaning executive alignment is predominantly tethered to clinical milestones and option grants rather than direct downside exposure.

---

5. Valuation, Reverse DCF & Margin of Safety

• Current Market Price: $2.04
• Intrinsic Fair Value (Probability-Weighted Triangulation): $2.84
• Margin of Safety (MOS): +28.2%
• Seth Klarman Downside Bear Floor: $0.95 (Liquidation Stub Value)
• Net Cash per Share: **$2.44** ($473.9M / 194.5M shares)
• Current Enterprise Value (EV): -$77.2 Million (Negative EV)

flowchart TD
    subgraph TriangulatedDCF["ValueMark Triangulated 3-Scenario Engine ($2.84 Fair Value)"]
        direction TB
        BEAR["<b>Bear Case (25% Weight) -> $0.95</b><br/>PERFORMA Fails / Elevates GI Discontinuation<br/>Trial Terminated | Term Loan Repaid<br/><i>Klarman Liquidation Floor: $0.95 ($185M Net Cash)</i>"]
        BASE["<b>Base Case (50% Weight) -> $2.60</b><br/>52-Wk Histology Meets Endpoint (~2029)<br/>Accelerated Approval + Ex-US Partnership<br/>$700M Peak MASH Sales | 12% Hurdle Rate<br/><i>Baseline Intrinsic Fair Value: $2.60</i>"]
        BULL["<b>Bull Case (25% Weight) -> $5.20</b><br/>Stellar MASH & ALD Data | Muscle Sparing Champion<br/>Strategic Big Pharma Buyout at $1.3B+<br/><i>Optimistic Acquisition Value: $5.20</i>"]
    end

    TRI["<b>Probability-Weighted Intrinsic Fair Value: $2.84</b><br/>(0.25 x $0.95) + (0.50 x $2.60) + (0.25 x $5.20) = $2.84<br/>Current Price: $2.04 | Margin of Safety: <b>+28.2%</b><br/><b>Dynamic Action Verdict: AVOID</b> (Failed 3 Knockout Gates)"]

    BEAR --> TRI
    BASE --> TRI
    BULL --> TRI

A. Triangulated 3-Scenario Valuation Engine (Rule 05)

Under ValueMark Rule 05, pre-commercial clinical biopharmaceutical companies are evaluated across three discrete, probability-weighted scenarios incorporating a 12.0% high-risk hurdle rate and factoring in future trial dilution:

1. Bear Case (25% Weight - Seth Klarman Downside Floor): $0.95 per share
   • Assumptions: The Phase 3 PERFORMA trial encounters insurmountable gastrointestinal tolerability hurdles (>25% dropout rate) or fails to demonstrate statistically significant fibrosis improvement over placebo at the Week-52 biopsy. Competitor dual agonists (survodutide) and next-generation oral incretins render pemvidutide commercially obsolete. Altimmune terminates clinical development. Over the intervening 2-3 years of wind-down, the company burns $250M in trial closure and operational overhead, pays off the$44.7M Hercules term loan, and liquidates remaining net cash of ~$185M across 195M shares, leaving a liquidation stub value of **$0.95 per share**.
2. Base Case (50% Weight - Baseline Accelerated Approval & Regional Deal): $2.60 per share
   • Assumptions: PERFORMA achieves its primary 52-week histologic endpoints in 2028-2029 (MASH resolution >=25% and fibrosis improvement >=1 stage without worsening of steatohepatitis). Supported by Breakthrough Therapy Designation, Altimmune files for FDA accelerated approval in late 2029. Management secures an ex-U.S. licensing partner providing $150M upfront, 50$700M peak worldwide net sales by 2035). Modeling 250M fully diluted shares (to reflect intermediate equity draws) and discounting future cash flows at 12.0% yields an equity value of $650M, or **$2.60 per share**.
3. Bull Case (25% Weight - Strategic Big Pharma Buyout): $5.20 per share
   • Assumptions: Pemvidutide confirms best-in-class hepatic fat clearance (>70%) and distinctive lean-muscle sparing in Phase 3 PERFORMA and Phase 2 ALD. A major multinational biopharmaceutical firm lacking proprietary glucagon IP (such as Pfizer, AstraZeneca, or Amgen) acquires Altimmune in a strategic transaction valued at $1.30 Billion net of debt, representing **$5.20 per share** (a ~155% premium to current market quotes).

$\text{Probability-Weighted Intrinsic Fair Value} = (0.25 \times \$0.95) + (0.50 \times \$2.60) + (0.25 \times \$5.20) = \$0.2375 + \$1.3000 + \$1.3000 = \mathbf{\$2.84}$

B. The Seth Klarman Bear-Floor Invariant

Under Rule 07 Section 5, value investors must subject any potential investment to the Seth Klarman Bear-Floor Rule: $\text{Strong Buy Floor Condition: Current Price} \le \text{Bear-Case Fair Value} \times 1.05$ With our conservative Bear-Case Liquidation Floor calculated at $0.95**, the maximum permissible purchase threshold for high-conviction buying is **$1.00. At the current market quotation of $2.04, ALT trades 114.7% above its Bear Floor.

Furthermore, while ALT offers a positive headline Margin of Safety of +28.2% against our base-case DCF fair value ($2.84), Rule 07 Section 5 mandates:

“Score < 60 (Failing Quality Gate): NEVER ELIGIBLE for Strong Buy or Buy. Action Verdict: AVOID (Value Trap / Fragile).”

Because Altimmune failed Knockout Gates K1, K2, and K4, no Margin of Safety—regardless of size—can justify capital commitment.

C. Reverse DCF Analysis (“Expectations Investing”)

Running an inverse DCF at the current market price of $2.04 demonstrates the market’s acute skepticism:

• Implied Pipeline Valuation: Market Cap ($396.7M) minus Net Cash ($473.9M) = -$77.2 Million.
• Mr. Market is currently assigning a negative value to pemvidutide, reflecting the market’s expectation that management will burn through the entire $518.6M cash reserve without ever achieving commercial profitability or an M&A exit.
• To justify the current stock price of $2.04 under a 12.0$75 Million in steady-state annual operating cash flow starting in 2031 (equivalent to just ~$250 Million in annual net sales).
• However, for fundamental value investors, low expectations cannot compensate for structural equity dilution, pre-commercial binary risk, and a three-year operational void until trial completion.

---

6. The 100-Point Master Value Score Breakdown

### Master Value Score Breakdown (100-Point System)
- **Pillar 1: Business Model Quality & Simplicity**: 6 / 20 pts
  - Simplicity & Predictability (1/5) | Repeat Demand (2/5) | Lynch Archetype (1/5) | Secular Runway (2/5)
- **Pillar 2: Economic Moat Durability**: 6 / 25 pts
  - Moat Depth & Source (3/8) | Moat Trend (2/6) | Gross Margin Shield (0/4) | SES Flywheel (0/4) | Spawner DNA (1/3)
- **Pillar 3: Financial Fortress & Solvency**: 9 / 20 pts
  - Leverage & Coverage (3/6) | Working Capital (4/4) | Refinancing Ladder (2/3) | Cash Conversion (0/4) | Forensic Check (0/3)
- **Pillar 4: Capital Allocation & Management**: 2 / 15 pts
  - ROIC/ROCE (0/5) | Incremental Returns / $1 Test (0/4) | Buyback Discipline (0/3) | Insider Incentives (2/3)
- **Pillar 5: Valuation, Margin of Safety & Asymmetry**: 7 / 20 pts
  - Margin of Safety (5/8) | Klarman Bear Floor (0/4) | Earnings/FCF Yield (0/3) | Lynch PEG / Katsenelson P/E (0/3) | Dhandho Asymmetry (2/2)

- **TOTAL MASTER VALUE SCORE**: **30 / 100** -> **Failing Quality Gate / Disqualified (Avoid)**
- **Action Verdict**: **AVOID** (MOS: +28.2% | Klarman Floor Premium: +115%)

---

7. What Would Invalidate the Thesis?

1. Transformative Big Pharma Out-Licensing Agreement: Signing a global licensing partnership with an elite pharmaceutical partner (e.g., Pfizer, AstraZeneca, Sanofi) that provides \ge \200 \text{ Million}$ in upfront non-dilutive licensing capital, commits the partner to fund 100% of remaining Phase 3 PERFORMA trial costs, and guarantees double-digit royalties, fundamentally solving the cash burn and commercialization deficits.
2. **All-Cash Strategic Acquisition Above $4.50**: Altimmune executing a definitive merger agreement to be acquired by a major pharmaceutical corporation at an all-cash premium exceeding$$4.50$ per share, delivering immediate capital realization for speculative holders.
3. Pivotal Phase 3 Histology Breakthrough: Top-line 52-week liver biopsy data from Cohort 1 of the PERFORMA trial demonstrating statistically significant MASH resolution ($>40\%$) and fibrosis improvement ($>30\%$) with gastrointestinal adverse event discontinuation rates falling below $10\%$, proving pemvidutide is clinically superior to existing commercial standards.
4. Market Capitulation to Klarman Bear Floor: Severe biotechnology sector liquidation driving ALT shares down to or below **$0.95 per share**, which would eliminate downside risk, expand Margin of Safety above$65%$, and provide pure Walter Schloss / Benjamin Graham net-net asset protection anchored by liquid cash.